Co-Diagnostics Overview

  • Founded
  • 2008
Founded
  • Status
  • Public
  • Employees
  • 37
Employees
  • Stock Symbol
  • CODX
Stock Symbol
  • Investments
  • 1
  • Share Price
  • $9.26
  • (As of Monday Closing)

Co-Diagnostics General Information

Description

Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV. The company's diagnostics systems enable very rapid, low-cost, sophisticated molecular testing for organisms and genetic diseases by greatly automating historically complex procedures in both the development and administration of tests.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Primary Office
  • 2401 South Foothill Drive
  • Suite D
  • Salt Lake City, UT 84109
  • United States
+1 (801) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Co-Diagnostics Stock Performance

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$9.26 $9.12 $7.01 - $30.99 $263M 28.9M 1.07M $1.84

Co-Diagnostics Financials Summary

In Thousands,
USD
TTM 31-Mar-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 226,159 235,623 12,979 18,935
Revenue 93,029 74,553 215 40
EBITDA 53,599 42,610 (6,060) (6,106)
Net Income 51,443 42,479 (6,196) (6,272)
Total Assets 81,119 71,237 2,215 1,553
Total Debt 0 0 0 1,909
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Co-Diagnostics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Co-Diagnostics‘s full profile, request access.

Request a free trial

Co-Diagnostics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies
Drug Discovery
Salt Lake City, UT
37 As of 2020
00.000
000000 - 000 00.000

0000-000

magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex
0000000000000
Sliema, Malta
000 As of 0000
0000
00.00 0000-00-00
000000&0 0000

0000000

. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla paria
0000000000000
London, United Kingdom
00 As of 0000
00.00 0000-00-00
000000&0
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Co-Diagnostics Competitors (7)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Fast-track Diagnostics Formerly Accelerator/Incubator backed Sliema, Malta 000 0000 000000&0 0000
0000000 00000000 Formerly Accelerator/Incubator backed London, United Kingdom 00 000000&0
00000-000 00000000 Corporate Backed or Acquired Laval, Canada 00 000000&0
000000 00000000000 Formerly PE-Backed New York, NY 000 00000 000000000 - 00000
0000 000000000000 Formerly VC-backed San Diego, CA 000 00000 00000000 00000
You’re viewing 5 of 7 competitors. Get the full list »

Co-Diagnostics Executive Team (6)

Name Title Board Seat Contact Info
Dwight Egan Chief Executive Officer & Chairman
Brian Brown Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Brent Satterfield Ph.D Chief Scientific Officer
Jesse Montgomery Chief Scientific Officer
Reed Benson General Counsel
You’re viewing 5 of 6 executive team members. Get the full list »

Co-Diagnostics Board Members (4)

Name Representing Role Since
Dwight Egan Co-Diagnostics Chief Executive Officer & Chairman 000 0000
James Nelson Co-Diagnostics Board Member 000 0000
Richard Serbin JD Co-Diagnostics Board Member 000 0000
You’re viewing 3 of 4 board members. Get the full list »

Co-Diagnostics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Co-Diagnostics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Co-Diagnostics‘s full profile, request access.

Request a free trial

Co-Diagnostics Investments (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000 00000000000 25-Jul-2017 00000 0000000 Other Healthcare
To view Co-Diagnostics’s complete investments history, request access »